Ensysce Biosciences, Inc. (ENSC)
CIK 1716947 · all EDGAR filings →
Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.
Shares outstanding over time
Latest: 19.5M shares as of Aug 12, 2026 (10-Q).⊙
Cash runway
Going-concern warning
auditor flagged substantial doubt
The company itself flagged going-concern doubt in a filing.
Full breakdown: cash runway tool · source filing →
Warrants
| Tranche | Warrants | Exercise price | Term | Notes |
|---|---|---|---|---|
| Institutional Investor | 652,439 | not tagged | — | — |
| Investor Warrants | 630,376 | $3.24 | — | — |
| Warrant One | 254,307 | $0.484 | — | — |
| Placement Agent Warrants | 22,063 | $0.6875 | — | — |
| Series B Warrants | not tagged | $15.9 | — | — |
Tranches exactly as the company dimensioned them in its 10-Q filed Aug 13, 2026 →. Groupings can overlap (a “Series E and F” row is not additive with a “Series E” row), so do not sum this column. A tranche the filer did not tag is absent here, not absent from the cap table. DOWN-ROUND = the filer tagged price-protection accounting scoped to that tranche.
Warrants outstanding: 254,307 underlying shares, as reported Apr 23, 2026 (10-Q).
Reported exercise price: $0.484 (aggregate figure as tagged; individual tranches vary).
Down-round (price protection) accounting has been tagged in this filer’s XBRL: some instrument carries repricing protection. Which tranche requires reading the exhibits.
Rough fully diluted estimate: 19.7M = 19.5M O/S + 254,307 warrant shares. An estimate, not a filing figure: it ignores converts, options and RSUs, and the two inputs carry different as-of dates.
Convertible notes
Reported conversion price: $0.55 (aggregate figure as tagged; individual notes can vary).
This filer tagged totals without per-note dimensions in its 10-Q filed Aug 13, 2026 →, so per-note terms (maturities, individual conversion prices) live in the exhibit prose and are not parsed here.
Fully diluted build-up
Shares outstanding plus every potential-share instrument the filer tagged in XBRL, each at its own as-of date. An estimate assembled from filed figures, not a filing figure itself.
| Shares outstanding | 19.5M | Aug 12, 2026 |
| + Institutional Investor (if exercised) | 652,439 | Mar 31, 2025 |
| + Investor Warrants (if exercised) | 630,376 | Mar 31, 2025 |
| + Warrant One (if exercised) | 254,307 | Apr 23, 2026 |
| + Placement Agent Warrants (if exercised) | 22,063 | Mar 31, 2025 |
| Fully diluted estimate | 21.0M | +8.0% vs O/S |
Still excluded, because the filer does not tag them in countable form: employee options and RSUs, any instrument living only in exhibit prose, and instruments above missing a share count. Inputs carry different as-of dates, shown per row. Each figure traces to the tranche and note tables above and their cited filings.
Registrations and offerings
Registered offering capacity on live registrations: $233.4Mfrom the structured fee exhibits; registered is not remaining, takedowns are not subtracted
Last 12 months: 4 executed · 4 registered.
Full history and shelf status: offering checker · S-3 shelf checker
Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.
Keep going: float checker · offering calendar · short-squeeze screener · full ENSC workspace
Free to use. No account, no card.